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Herpesviruses characteristically transmit infection from
immune hosts. Although their success in escaping
neutralization by pre-formed antibody is indisputable,
the underlying molecular mechanisms remain largely
unknown. Glycoprotein B (gB) is the most conserved
component of the herpesvirus entry machinery and its N
terminus (gB-NT) is a common neutralization target. We
used murid herpesvirus-4 to determine how gB-NT con-
tributes to the virus–antibody interaction. Deleting gB-NT
had no obvious impact on virus replication, but paradoxi-
cally increased virion neutralization by immune sera. This
reﬂected greater antibody access to neutralization epitopes
on gH/gL, with which gB was associated. gB-NT itself was
variably protected against antibody by O-linked glycans;
on virions from epithelial cells it was protected almost
completely. gB-NT therefore provides a protective and
largely protected cover for a vulnerable part of gH/gL.
The conservation of predicted glycosylation sites in other
mammalian herpesvirus gB-NTs suggests that this evasion
mechanism is widespread. Interestingly, the gB-NT gly-
cans that blocked antibody binding could be targeted for
neutralization instead by a lectin, suggesting a means of
therapeutic counterattack.
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Introduction
Neutralizing antibody is the sine qua non of anti-viral vac-
cines (Zinkernagel and Hengartner, 2006). Persistent viruses
present a major challenge to vaccine development because
they have evolved to coexist with antibody. Developing new
strategies to control their spread means understanding
why neutralization normally fails (Burton et al, 2005).
Herpesviruses are among the most sophisticated of all persis-
tent viruses and provide a template for understanding some
of the limits viruses impose on antibody function. Once a
herpesvirus has entered its host, latency and cell–cell spread
(Peeters et al, 1993; Dingwell et al, 1994) offer few opportu-
nities for neutralization; antibody must act instead through
mechanisms such as cytotoxicity (Sissons and Oldstone,
1980). a- and b-Herpesviruses counteract this with viral IgG
Fc receptors (Johnson and Feenstra, 1987; Nagashunmugam
et al, 1998; Atalay et al, 2002). g-Herpesviruses may not
need to because their host colonization depends more on
latency-associated lymphoproliferation than on lytic spread
(Stevenson et al, 1999; Coleman et al, 2003). In contrast to
cell–cell spread within hosts, herpesviruses transmit between
hosts as cell-free virions. These are potentially vulnerable to
neutralization. However, herpesviruses enter and exit im-
mune hosts (Sitki-Green et al, 2003) without even much
selection of antigenic variants (Xu et al, 1996). It is difﬁcult
to know exactly how much antibody each virion encounters,
but antibody is abundant in the mucosal sites from where
g-herpesviruses are shed (Yao et al, 1985), and any antigen
excess would presumably just elicit more antibody. An anti-
body excess therefore seems likely. Other mucosal infections
make it clear that even quite low antibody amounts can
signiﬁcantly reduce infectivity if neutralization is efﬁcient
(Mozdzanowska et al, 2003). g-Herpes virions must therefore
resist neutralization.
Reconciling reports of in vitro g-herpesvirus neutralization
(Thorley-Lawson and Poodry, 1982; Stevenson and Doherty,
1998; Dialyna et al, 2004) with the evident lack of in vivo
neutralization raises two important issues. First, neutraliza-
tion aimed at cell binding may be cell type-speciﬁc. Thus, the
Epstein–Barr virus gp350 is a neutralization target for B-cell
infection (Thorley-Lawson and Poodry, 1982) but not for
epithelial infection (Janz et al, 2000), which gp350-speciﬁc
antibodies even promote (Turk et al, 2006). Similarly, im-
mune sera block ﬁbroblast binding by murid herpesvirus-4
(MuHV-4) (Gill et al, 2006), but fail to block and even
enhance its infection of IgG Fc receptor-bearing cells (Rosa
et al, 2007). Second, neutralization often reﬂects reduced
rather than ablated infectivity. The requirements for each
may be qualitatively distinct, for example if not all the copies
of a virion glycoprotein are equally susceptible to antibody
binding.
MuHV-4 provides a means to identify key, common themes
in g-herpesvirus antibody evasion. Robust neutralization
generally targets essential virion proteins, and MuHV-4 is
no exception: its only mAb-deﬁned neutralization targets are
glycoprotein B (gB) and gH/gL (Gill et al, 2006; Gillet et al,
2006). Both are conserved in all mammalian herpesviruses
and essential for infectivity (Forrester et al, 1992; Heldwein
et al, 2006). The gB N terminus (gB-NT) is a neutralization
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5131target for many herpesviruses, including MuHV-4 (Ohlin
et al, 1993; Holloway et al, 1998; Akula et al, 2002; Gillet
et al, 2006; Okazaki et al, 2006). The basis for this neutraliza-
tion is not clear. The herpes simplex virus gB-NT has a non-
essential heparin-binding function (Laquerre et al, 1998) and
the Kaposi’s Sarcoma-associated herpesvirus gB-NT binds to
integrins (Akula et al, 2002), but gB-NT-directed MuHV-4
neutralization blocks infection at a post-binding step close
to membrane fusion (Gillet et al, 2006). To understand how
gB-NTcontributes to the virus–antibody interaction, we have
deleted it from MuHV-4.
Results
gB-NT is non-essential for MuHV-4 infection
To establish the functional importance of gB-NT, we intro-
duced one of three deletions, removing amino-acid residues
2–6, 2–14 or 2–30 after the predicted MuHV-4 gB signal
sequence (Figure 1A). (Its ﬁrst conserved cysteine is residue
39.) All these mutants retained infectivity. Southern blots
conﬁrmed their predicted genomic structures (Figure 1B).
Immunoﬂuorescence showed no obvious effect of gB-NT
deletion on gB expression in infected cells (Figure 1C) and
immunoblots established that the gB content of each mutant
was comparable to that of wild-type virus (Figure 1D and E).
Growth curves (Figure 2A) established that gB-NTwas not
required for MuHV-4 lytic propagation. Nor did any of the
mutants show reduced cell binding (Figure 2B). gB is a cell-
binding protein of MuHV-4 (Gillet et al, 2007a), but gB-NT
deletions did not affect cell binding by the N-terminal half of
gB fused to IgG Fc (Figure 2C). Nor did a gB-NT-speciﬁc
neutralizing mAb block cell binding by gB-Fc (Figure 2D),
consistent with the idea that these mAbs do not act by
blocking binding (Gillet et al, 2006). We considered that gB-
NT might instead be important for B-cell infection. However,
the gB-NT deletion mutants infected NS0 myeloma cells
much like wild-type MuHV-4 (Figure 2E). The 2–14 and 2–
30 deletion mutants (the 2–6 mutant was not tested) also
showed no deﬁcit in colonizing the lungs and spleens of mice
after intranasal infection (Figure 2F–H). gB-NTwas therefore
not important for entry.
Altered antigenicity of MuHV-4 lacking gB-NT
Our subsequent analysis focused on the largest gB-NT dele-
tion (gBD2–30). The virions found on infected cell surfaces
(de Lima et al, 2004) provide a means of probing antigenic
differences between MuHV-4 glycoprotein mutants. As ex-
pected, gB-NT-speciﬁc neutralizing mAbs—previously
mapped to gB residues 1–40 (Gillet et al, 2006)—did not
recognize cells infected with gBD2–30 MuHV-4 (Figure 3A).
gB recognition by several other mAbs was also affected.
Thus, mAb MG-1A12 recognized the gBD2–30 mutant slightly
better than wild type (mean ﬂuorescence intensity (MFI) 352
versus 192), whereas mAb BN-2A4 recognized the mutant
Figure 1 Generation of MuHV-4 mutants lacking gB-NT. (A) The indicated regions of the gB coding sequence were removed and replaced with
an EcoRI site. (B) Southern blotting showed the predicted introduction of an EcoRI restriction site for each deletion mutant (gBD2–6, gBD2–14,
gBD2–30). REV, revertant of the gBD2–30 mutant. (C) Immunoﬂuorescence of cells infected with the largest deletion mutant (gBD2–30) showed
no effect on gB expression in either BHK-21 ﬁbroblasts or NMuMG epithelial cells. gB-speciﬁc staining is black in this reversed image. Similar
staining was observed with the gBD2–6 and gBD2–14 mutants. (D) Immunoblot of wild-type (WT), gBD2–6, gBD2–14 and gBD2–30 virions
with the gB-C-speciﬁc mAb MG-4D11. REV, revertant of the 2–30 deletion mutant; gB-FL, uncleaved gB; gB-C, C-terminal half of furin-cleaved
gB (Lopes et al, 2004), which contains the MG-4D11 epitope. The ORF17-speciﬁc mAb 150-7D1 was included in the same blot to give a loading
control. The two ORF17 bands correspond to a post-translational cleavage, as described for the homologous herpes simplex virus UL26.
(E) Unreduced gB immunoblotted with mAb MG-4D11 shows a single major band (gB-FL) since the furin-cleaved gB fragments are held
together by disulﬁde bonds. Higher molecular weight forms are presumably gB multimers or aggregates.
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be close to gB-NT. For example, the BN-2A4 epitope could
partly incorporate gB-NT and the MG-1A12 epitope could be
partly obscured by it. The normal infectivity of the gBD2–30
mutant made it unlikely that gBD2–30 was substantially
misfolded.
A second and more surprising effect of gB-NT deletion
was greater accessibility of gH/gL-neutralizing epitopes
(Figure 3B). Thus, while mAbs LT-6E8 (anti-gp70), 3F7
(anti-gN) and BN-3A4 (anti-gp150) stained the gBD2–30
mutant no more than wild type, the gH/gL-speciﬁc mAbs
7E5, T4C5 and 230-5H6 all stained the mutant slightly better
(MFI 334 versus 233, 334 versus 209 and 225 versus 109,
respectively for BHK-21 cells). 7E5 and T4C5 deﬁne two gH/
gL neutralization epitopes (Gill et al, 2006). MAb 230-5H6
always showed the greatest difference, but all the differences
were highly reproducible and statistically signiﬁcant. They
did not reﬂect greater gH/gL expression, since the gH-speciﬁc
mAb 8C1 and another gH/gL-speciﬁc mAb, 230-4A2, showed
equivalent expression between the mutant and wild type.
Instead it appeared that neutralization epitopes on gH/gL
were selectively exposed by gB-NT deletion. Increased gH/gL
Figure 2 Propagation and cell binding of gB-NT deletion mutants. (A) BHK-21 cells were infected (0.01p.f.u./cell) with wild-type (WT) MuHV-
4, each deletion mutant or a revertant of the gBD2–30 mutant (REV). Virus growth with time was then monitored by plaque assay. (B) EGFP
þ
version of the same viruses as in (A) was added to BHK-21 cells (1p.f.u./cell) for the time indicated, then washed with PBS to remove unbound
virions. The cells were then cultured overnight and infection was quantitated the next day by ﬂow cytometric assay of viral eGFP expression.
Equivalent data were obtained in two further experiments. (C) NMuMG cells were stained with gB-Fc fusions recovered from supernatants
of transfected 293Tcells. The shaded histogram is staining with secondary antibody only. None of the gB-NT deletions affected cell binding.
(D) The gB-Fc fusion protein was pre-incubated with the neutralizing gB-NT-speciﬁc mAb MG-2C10 before being used to stain NMuMG cells.
No difference in staining was observed. (E) NS0 myeloma cells were exposed (18h) to eGFP
þ wild-type (WT) MuHV-4 or gB-NT deletion
mutants. Infection was then quantitated by ﬂow cytometric assay of viral eGFP expression. (F) Mice were infected intranasally with wild-type
(WT) MuHV-4, the gBD2–14 or gBD2–30 mutant or a revertant of the gBD2–30 mutant (REV). Lungs were harvested at 6 days post-infection
and infectious virus quantitated by plaque assay. Each bar shows the mean7s.e.m. titers of ﬁve mice per group. (G) At 14 days after infection
as for (B), spleens were harvested and virus load measured by infectious center assay. Each bar shows the mean7s.e.m. titers of ﬁve mice per
group. (H) DNA was extracted from the same spleens as in (C) and assayed for viral genome load by real-time PCR. Each bar shows the
mean7s.e.m. of ﬁve mice per group.
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ﬂuorescence (Figure 3C). Here, we bound virions to cells
rather than using infected cells, so as to present a more
deﬁned antigen. Both wild-type and gBD2–30 virions were
readily visualized by staining for gN, but the 230-5H6 epitope
of gH/gL was poorly displayed unless gB-NT was deleted.
An effect of gB on gH seemed plausible because these
proteins are associated in MuHV-4 virions (Figure 3D). This
association was independent of gB-NT, but provided a
physical basis for gB-NT contacting gH/gL.
Increased susceptibility of gBD2–30 MuHV-4 to
gH/gL-directed neutralization
As expected, the gBD2–30 mutant was no longer susceptible
to gB-NT-speciﬁc neutralizing mAbs (Figure 4A). However,
despite the removal of this neutralization epitope, immune
sera neutralized the gBD2–30 mutant better than wild
type (Figure 4B). There was no obvious difference in
neutralization titer between wild-type-immune and gBD2–
30-immune sera, arguing that neutralization did not
depend on a new epitope created by the gB-NT deletion,
Figure 3 Antigenicity of the gBD2–30 fusion complex. (A) BHK-21 cells were infected (2p.f.u./cell, 18h) with wild-type (solid lines) or gBD2–
30 mutant (dotted lines) MuHV-4, and then analyzed by ﬂow cytometry. The ﬁlled histogram shows uninfected cells. MAb 15G9 recognizes gB-
NT, mAb BN-2A4 recognizes an epitope elsewhere in the N-terminal half of gB and mAb MG-1A12 recognizes a complex gB epitope. (B) BHK-
21 or NMuMG cells were infected as for (A) and analyzed by ﬂow cytometry for the expression of other MuHV-4 glycoproteins. Again, the
dotted line corresponds to the gBD2–30 mutant and the solid line corresponds to wild type. The ﬁlled histogram shows secondary antibody only
staining. Each histogram shows 30000 events. The reduction in gH/gL staining for T4C5, 7E5 and 230-5H6 were all statistically signiﬁcant
(Po0.001 by Student’s t-test). Equivalent data were obtained in four further experiments. (C) NMuMG cells were exposed to wild-type (WT) or
gBD2–30 virions (2h, 41C), then washed with PBS and ﬁxed with 2% paraformaldehyde. The cells were then stained for gN with mAb 3F7 and
for gH/gL with mAb 230-5H6. Nuclei were counter-stained with DAPI. (D) Wild-type (WT) and gBD2–30 virions were lysed in 1% digitonin. gH
was immunoprecipitated with mAb 8C1 (IgG2b). The original lysates and the precipitates (IP gH) were then immunoblotted for gB-C with mAb
MG-4D11 and for gN with mAb 3F7 (both IgG2a) May et al (2005). Detection was with an IgG2a-speciﬁc secondary antibody. The positions of
gN and full-length (gB-FL) and cleaved (gB-C) gB are marked. While both gB and gN were present in the lysates, only gB was co-precipitated
with gH. No difference in co-precipitate was observed between the gBD2–30 mutant and wild type. Equivalent data were obtained in two
further experiments.
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wild-type MuHV-4.
We then selected mAbs from wild-type MuHV-4-immune
mice by their capacity to neutralize the gB-NT mutant. All
(n¼10) recognized gH/gL. Previously established gH/gL-
speciﬁc mAbs also neutralized the gBD2–30 mutant better
than wild type (Figure 4C). This was consistent with the
greater accessibility of gH/gL epitopes observed for gBD2–30-
infected cells (Figure 3B) and gBD2–30 virions (Figure 3C).
Notably, mAb 230-5H6 showed the greatest difference
between the gBD2–30 mutant and wild type in both staining
and neutralization. In contrast to the improved gH/gL-speci-
ﬁc neutralization, a gB-speciﬁc neutralizing mAb (BH-6B5)
that recognizes a region of gB outside gB-NT showed no
difference between the gBD2–30 mutant and wild type
(Figure 4C). We tested further the gH/gL dependence of
gBD2–30 virus neutralization by comparing sera from mice
infected with gL
þ and gL
  MuHV-4 (Figure 4D and E). The
latter make no gH/gL-speciﬁc antibody response, since
gL
  MuHV-4 does not display gH/gL epitopes (Gillet et al,
Figure 4 Neutralization of the gBD2–30 mutant. (A) Wild-type (WT) and gB-NT deletion virions were incubated with the gB-NT-speciﬁc
neutralizing mAb MG-2C10, then assayed for infectivity on BHK-21 cells. Equivalent data were obtained in two further experiments. (B) Sera
from mice infected with wild-type (WT) or gBD2–30 MuHV-4 were used to neutralize WTor gBD2–30 virions for BHK-21 cell infection. Each of
the six serum samples is from one mouse. Equivalent data were obtained in four further experiments, using different immune sera. We
compared titers by w
2 test (scoring as more or less than the interpolated median) for all the sera at each dilution. In the experiment shown, ﬁve
of six serum dilutions showed a signiﬁcant difference in neutralization (Po0.05) between WTand gBD2–30 viruses. Each repeat experiment
showed signiﬁcant differences at more than half the dilutions tested. (C) Wild-type (WT) and gBD2–30 virions were exposed to different
neutralizing mAbs, then assayed for infectivity on BHK-21 cells. BH-6B5 is gB speciﬁc but not gB-NTspeciﬁc. Scoring the titer for each virus to
the average for that dilution and then comparing the values for all the dilutions of an assay by w
2 test showed that gH/gL-speciﬁc mAbs
neutralized the gBD2–30 mutant signiﬁcantly better than the wild type (Po0.002). Equivalent data were obtained in four further experiments.
(D) Wild-type (WT) and gBD2–30 virions were exposed to sera from mice infected with WTor gL-deﬁcient (gL
 ) MuHV-4. Both showed greater
neutralization of the gBD2–30 mutant, but the difference was greater for wild-type-immune sera. (E) Equivalent results to (D) for ﬁve different
immune sera in each group at a single serum dose (2.5ml/1000p.f.u. virus). Wild-type-immune sera showed a signiﬁcant difference in
neutralization between wild-type and gBD2–30 virions (Po0.002 by Student’s t-test). The gL
 -immune sera did not (P¼0.14).
Herpesvirus antibody evasion
L Gillet and PG Stevenson
&2007 European Molecular Biology Organization The EMBO Journal VOL 26 | NO 24 | 2007 51352007c). While wild-type-immune sera showed better neutra-
lization of the gBD2–30 mutant, gL knockout-immune sera
did not. gB-NT deletion therefore conferred a greater suscept-
ibility to neutralization by exposing gH/gL.
This neutralization also operated in vivo (Table I). Thus,
immune sera blocked the entry of gBD2–30 MuHV-4 into new
hosts much more effectively than that of the wild type.
Immune sera normally block intranasal MuHV-4 infection
poorly because they poorly inhibit membrane fusion; this can
be remedied by boosting anti-gH/gL immunity (Gillet et al,
2007d). Thus, the increased susceptibility of the gBD2–30
mutant to in vivo neutralization was consistent with its
greater vulnerability to gH/gL-speciﬁc antibodies.
Cell type-speciﬁc susceptibility to gB-NT-directed
neutralization
Since gB-NT itself can be a neutralization target, why should
exchanging a gB-NT target for one on gH/gL affect overall
virion susceptibility to neutralization? The obvious explana-
tion would be that these targets are not equivalent. We have
noted before that mAbs speciﬁc for gB-NT neutralize MuHV-4
only to a threshold minimum, not to zero (Gillet et al, 2006).
Moreover, while plaque formation on BHK-21 ﬁbroblasts is
blocked quite well, plaque formation on NMuMG epithelial
cells is blocked hardly at all. These data suggested that gB-
NT-directed neutralization might be less effective than it
appeared from assays using ﬁbroblasts, and so might be
less important to MuHV-4 than gH/gL-directed neutraliza-
tion. We therefore sought to deﬁne how gB-NT might itself
evade antibody.
One question raised by the difference in gB-NT-directed
neutralization between NMuMG epithelial cells and BHK-21
ﬁbroblasts was whether this reﬂected different entry require-
ments or differences in the virions produced, once an initial
infection had occurred. To answer this, we compared
NMuMG-derived and BHK-derived virions for their suscept-
ibility to neutralization (Figure 5A). Each was similarly
susceptible to gH/gL-directed neutralization, but NMuMG
cell-derived virions were much less susceptible to gB-NT-
directed neutralization for both BHK-21 and NMuMG cell
infections. Thus, the difference in neutralization reﬂected
mainly a difference between the virions each cell type pro-
duced.
As before, we examined gB antigenicity by ﬂow cytometry
of virus-infected cells (Figure 5B). MuHV-4-infected NMuMG
cells showed more total gB-speciﬁc staining than infected
Table I gB-NT protects against neutralization in vivo
Challenge Neutralization Mice infected
Wild type gBD2–30
100p.f.u. Nil 10/10 10/10
100p.f.u. BALB/c immune serum 4/10 0/10
100p.f.u. C57BL/6 immune serum 2/10 0/10
1000p.f.u. Nil 10/10 10/10
1000p.f.u. BALB/c immune serum 10/10 0/10
1000p.f.u. C57BL/6 immune serum 10/10 0/10
Wild-type and gBD2–30 virions were incubated (2h, 371C) with or
without immune sera (5ml) pooled from mice 3-6 months post-
infection with wild-type MuHV-4. They were then inoculated in-
tranasally into naive mice. The mice were assayed for infection or
not 7 days later by titering infectious virus in lungs. Signiﬁcant
differences were observed from the pooled BALB/c immune sera at
100p.f.u. (Po0.05 by w
2 test) and for both serum pools at 1000p.f.u.
(Po10
 5). No signiﬁcant difference was observed between sera
from C57BL/6 and BALB/c mice.
Figure 5 MuHV-4 virions derived from BHK-21 ﬁbroblasts and NMuMG epithelial cells differ in gB-NTantigenicity and in susceptibility to gB-
NT-directed neutralization. (A) Virions from BHK-21 or NMuMG cells were incubated with gH/gL-speciﬁc or gB-NT-speciﬁc neutralizing mAbs,
then titered on BHK-21 or NMuMG cells. The difference in gB-NT-directed neutralization between BHK-21-derived and NMuMG-derived virions
was signiﬁcant by w
2 test for both BHK-21 and NMuMG cells (Po0.002). Equivalent data were also obtained in two further experiments.
(B) BHK-21 or NMuMG cells were infected with MuHV-4 and 18h later analyzed for cell surface gB expression by ﬂow cytometry. MAbs MG-
10C11 and MG-15G9 are gB-NT-speciﬁc and neutralizing, MG-4A1 and MG-4D11 are not gB-NT-speciﬁc and non-neutralizing. The difference in
MFI between MG-10C11/MG-15G9 and MG-4A1/MG-4D11 was signiﬁcantly greater for NMuMG cells (44-fold) than for BHK-21 cells (o2-
fold). Equivalent data were obtained in two further experiments. (C) BHK-21- and NMuMG-derived virions were immunoblotted for gB-NT
(mAb MG-2C10) plus ORF17 as a loading control (mAb 150-7D1), or for gB-C (mAb MG-4D11). The positions of uncleaved gB (gB-FL), its
cleavage products (gB-N, gB-C) and ORF17 are marked.
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versus 40 for MG-4D11), probably reﬂecting greater virion
accumulation on the plasma membrane. But they displayed
relatively less of the gB-NT neutralization epitope (MFI 77
versus 51 for mAbs MG-10C11 and 79 versus 46 for MG-
15G9). Immunoblots (Figure 5C) showed a similar gB content
for NMuMG- and BHK-derived virions based on staining with
the gB-C-speciﬁc mAb MG-4D11, but gB-NT of NMuMG-
derived virions was recognized substantially less well. The
65kDa band in Figure 5C is cleaved N-terminal gB, which is
abundant in mature virions. The less abundant 120kDa band
is uncleaved gB. The different bands around 120kDa prob-
ably correspond to different N-linked gB glycoforms (Lopes
et al, 2004). The poor recognition of these bands of NMuMG-
derived virions by mAb MG-2C10 indicated that gB-NT was
antigenically different.
O-linked glycans protect gB against neutralization
The MuHV-4 gB-NT contains nine potential O-glycosylation
sites (Figure 6A). Despite considerable sequence diversity
between the gB-NTs of different herpesviruses, multiple pre-
dicted O-glycosylation sites are preserved. Human cytomega-
lovirus and bovine herpesvirus-4 provide particularly striking
examples. Our gB-NT-speciﬁc neutralizing mAbs do not
require O-glycans for recognition, since they recognize bac-
terially expressed gB fragments (Gillet et al, 2006), but
O-glycans could potentially inhibit their recognition. We
tested this by digesting NMuMG cell-derived virion lysates
with sialidase A plus O-glycanase (Figure 6B). This gave a
marked improvement in gB detection. In contrast, removing
N-linked glycans had no effect.
We then removed O-glycans from intact, NMuMG cell-
derived virions. This conferred susceptibility to gB-directed
neutralization (Figure 6C). The neutralization of BHK-21 cell-
derived virions also improved, consistent with the previously
noted failure of gB-NT-speciﬁc mAbs to eliminate their in-
fectivity completely (Gillet et al, 2006). Thus, gB-NT on
NMuMG cell-derived virions was strongly protected against
neutralization by O-glycans, and the greater susceptibility of
BHK-21 cell-derived virions to gB-NT-directed neutralization
correlated with less O-glycan-dependent protection. gB-NT O-
glycosylation also explained why deleting just a few amino-
acid residues noticeably reduced the gB apparent molecular
weight (Figure 1D and E).
O-glycans protect ex vivo virions against neutralization
The g-herpes virions shed by infected hosts are probably
derived from epithelial cells (Jiang et al, 2006). These char-
acteristically produce extensively O-glycosylated mucins
(Patton et al, 1995). They may therefore produce extensively
O-glycosylated virions. Virions recovered from lung homo-
genates of MuHV-4-infected mice showed substantial
O-glycan-dependent resistance to gB-directed neutralization
(Figure 6D). Similar results were obtained with virions
recovered by bronchoalveolar lavage (data not shown).
Thus, the resistance of NMuMG cell-derived virions to neu-
tralization was consistent with the situation in vivo.I n
contrast, the susceptibility of BHK-21 cell-derived virions to
gB-NT-directed neutralization probably underestimates the
obstacles that antibody normally faces.
gB-NT O-glycans can be a target for lectin-mediated
neutralization
Since gB-NT was non-essential for MuHV-4 replication, gB-
NT-directed neutralization probably operates by steric hin-
drance, for example by keeping fusion loops away from host
membranes. This suggested that any bulky molecule in the
same site might inhibit infection equally well. We therefore
tested the capacity of jacalin, an O-glycan-speciﬁc lectin, to
inhibit MuHV-4 infection (Figure 7A). Inhibition was evident
for NMuMG cell-derived but not for BHK-21 cell-derived
virions, the converse of antibody-mediated neutralization.
We used biotinylated jacalin so as to also attach streptavi-
din-conjugated phycoerythrin (molecular weight 300kDa),
but biotinylated jacalin alone (60kDa) was also effective.
Removing O-glycans from MuHV-4 propagated in NMuMG
cells, the same treatment that conferred susceptibility to
neutralization by mAbs, abolished the inhibition by jacalin
(Figure 7B). Probably multiple virion glycoproteins are differ-
entially glycosylated between NMuMG and BHK-21 cells.
However, the gBD2–30 mutant escaped inhibition by jacalin
when propagated in NMuMG cells (Figure 7C). Lectin-
mediated neutralization was therefore speciﬁc to gB-NT.
Discussion
Epidemiology tells us that herpesviruses evade neutralization
by antibody (Xu et al, 1996). There is no evidence for weak
immunogenicity, indeed persistent infection potently elicits
both serum and mucosal antibody responses (Gyselink et al,
1978; Tamura et al, 1980; Yao et al, 1991). But while most
viruses cannot transmit from immune hosts without anti-
genic variation, herpes virions readily do so. Most neutraliz-
ing antibodies block receptor binding (Knossow and Skehel,
2006). A key part of herpesvirus antibody evasion may
therefore be a capacity to infect via alternative uptake path-
ways such as IgG Fc receptors (Inada et al, 1985; Maidji et al,
2006; Rosa et al, 2007; Gillet et al, 2007b). But even if virions
evade a block to cell binding, they remain potentially suscep-
tible to a block to membrane fusion. The data presented here
provide the ﬁrst insights into how g-herpesviruses can protect
their fusion machinery against antibody.
MAbs directed against the MuHV-4 fusion complex are
strikingly inefﬁcient at neutralization: those binding to gB
cannot ablate infectivity completely (Gillet et al, 2006), and
those binding to gH/gL require a very large antibody excess
(Gill et al, 2006). gB-NT played a central role in both aspects
of antibody resistance: it protected a critical region of gH/gL,
and was itself protected by O-linked glycans. Removing gB-
NT made a subset of gH/gL epitopes more accessible, imply-
ing that gB-NT covers a crucial part of gH/gL. The redun-
dancy of gB-NT for the gB/gH/gL interaction suggested that
its interaction with gH/gL was weak; the partial availability of
the 230-5H6 epitope on wild-type virions suggested that it
might even be reversible. gB-NT is presumably displaced
from gH/gL after virions engage the cell surface. This may
stop antibodies binding to neutralization epitopes on gH/gL
unless they are co-endocytosed, which would explain why
gH/gL-directed neutralization requires a large antibody
excess.
The protection of gB-NT itself by O-linked glycans illus-
trates two important points: susceptibility to neutralization
may depend on the cell type producing the virus; and
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the ease of infection control. Although gB-NT-speciﬁc mAbs
could largely neutralize ﬁbroblast-derived virions, they al-
most completely failed to neutralize epithelial cell-derived
virions. Ex vivo virions also showed substantial resistance.
The conservation of predicted O-glycosylation sites in other
herpesvirus gB-NTs suggests that this evasion mechanism is
widespread; indeed, much as N-linked glycans protect con-
formational epitopes (Burton et al, 2005; Knossow and
Skehel, 2006), O-glycans could protect linear epitopes on
many viral glycoprotein N termini. Despite O-glycosylation,
gB-NTs may eventually be targeted well enough to reduce
viral transmission. This could explain what appears to be
weak selection for herpesvirus gB-NT amino-acid diversity
(Basgoz et al, 1992; Xu et al, 1996; Auerbach et al, 2000). The
recorded amino-acid diversity by itself would seem insufﬁ-
cient for antibody evasion—HIV and inﬂuenza vary much
more—but could act by modulating O-glycosylation
(Mardberg et al, 2004). Bovine herpesvirus-4, which is parti-
cularly rich in potential O-linked glycan attachment sites,
Figure 6 O-linked glycans mask gB-NT of NMuMG cell-derived virions. (A) Herpesvirus gB alignment from the predicted signal sequence
cleavage site to the ﬁrst conserved cysteine residue, with potential glycosylation sites, both N- and O-linked, in upper case. (B) Reduced MuHV-
4 virion lysates derived from BHK-21 (BHK) or NMuMG cells (NMu) were either left untreated or deglycosylated as indicated, then
immunoblotted for gB-NT with mAb MG-2C10 or for gB-C with mAb MG-4D11. (C) Intact BHK-21 or NMuMG cell-derived virions were
deglycosylated without denaturation. /, no enzyme, N
 , protein N-glycanase, O
 , sialidase AþO-glycanase. Each was then immunoblotted for
gB-NT/gB-C and tested for neutralization. MAbs MG-15G9 and MG-2H4 are gB-NT-speciﬁc, T2C12 is gH/gL-speciﬁc. Equivalent data were
obtained in two further experiments. Comparing results for all the experiments by Student’s t-test, T2C12 neutralization was not signiﬁcantly
different between untreated and deglycosylated samples, whereas MG-15G9 and MG-2H4 showed a signiﬁcant improvement in neutralization
with deglycosylation for both BHK-21 cells (Po0.02) and NMuMG cells (Po0.001). (D) MuHV-4 virions were recovered from infected mouse
lungs, deglycosylated (O-glycanase) or not (no treatment) as in (C), then exposed to gH/gL-speciﬁc (T2C12) or gB-NT-speciﬁc (MG-2C10)-
neutralizing mAbs. The improvement in gB-NT-directed neutralization by deglycosylation was signiﬁcant by w
2 test (Po0.002). Equivalent data
were obtained in a repeat experiment.
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(Vanderplasschen et al, 2000), which could modify gB-NT
further. Thus, while herpesviruses generally pursue a faithful
replication strategy, more subtle forms of antigenic variation
may not be beyond them.
Although O-glycan binding mAbs can occur (Burton et al,
2005), T-cell tolerance makes them rare. In essence, O-gly-
cans like N-glycans provide an antibody-proof shield.
However, glycans provide potential binding sites for lectins
(Wilson et al, 1999; Rudiger and Gabius, 2001). The extensive
N-glycosylation of the HIV gp120 makes it a target for
N-glycan-binding lectins (Balzarini, 2006). Our data show
that an O-glycan-binding lectin can reduce herpesvirus in-
fectivity. A combination of lectins and antibody could be
particularly effective, since the evasion of one predisposed to




Female BALB/c mice were purchased from Harlan UK Ltd (Bicester,
UK), housed in the Cambridge University Department of Pathology,
and infected intranasally with MuHV-4 (2 10
4p.f.u.) when 6–8
weeks old (Home Ofﬁce Project Licence 80/1992). Immune sera
were collected at least 3 months post-infection. Ex vivo virus was
recovered from lung homogenates 5 days post-infection. Cell debris
was pelleted by centrifugation (1000g, 5min) three times. Super-
natant virus was then recovered by ultracentrifugation (38000g,
90min).
Cells
BHK-21 cells, NMuMG cells, NIH-3T3-CRE cells (Stevenson et al,
2002), 293Tcells and NS0 cells were grown in Dulbecco’s modiﬁed
Eagle’s medium (Invitrogen, Paisley, UK) supplemented with 2mM
glutamine, 100U/ml penicillin, 100mg/ml streptomycin and 10%
fetal calf serum (PAA Laboratories, Linz, Austria). Medium for
murine embryonic ﬁbroblasts was further supplemented with
50mM 2-mercaptoethanol. Cells were transfected where indicated
using Fugene-6 (Roche Diagnostics, Lewes, UK).
Viruses
All viruses were derived from a cloned MuHV-4 BAC (Adler et al,
2000). The coding sequence for amino-acid residues 2–6 (PTTLR),
2–14 (PTTLRQPSDMTPA) or 2–30 (PTTLRQPSDMTPAQDAP-
TETPPPLSTNTN) of the mature gB were replaced with an EcoRI
restriction site (encoding EF). We ﬁrst PCR-ampliﬁed (Phusion DNA
polymerase; New England Biolabs, Hitchin, UK) coordinates
15001–16600 of the MuHV-4 genome (Virgin et al, 1997), including
KpnI and EcoRI restriction sites in the respective 50 and 30 primers,
and cloned the PCR product into the KpnI/EcoRI sites of pSP73
(Promega Corporation, Southampton, UK). We then ampliﬁed
genomic coordinates 16616–18025, 16640–18025 or 16688–
18025 as EcoRI/BglII-restricted fragments and cloned these into
the corresponding sites of the same vector. This generated the
relevant deletions between genomic ﬂanks of approximately 1.6kb.
Each construct was then subcloned as a BglII/KpnI fragment into
the BamHI/KpnI sites of the pST76K-SR shuttle vector, and
recombined into the MuHV-4 BAC (Adler et al, 2000). The correct
construction of each mutant was conﬁrmed by DNA sequencing.
Infectious virus was reconstituted by transfecting each BAC into
BHK-21 cells. Except where indicated, the loxP-ﬂanked BAC/eGFP
cassette was removed by virus passage in NIH-3T3-CRE cells,
and virus stocks were grown in BHK-21 cells and titered by plaque
assay in BHK-21 cells. gL-deﬁcient MuHV-4 has been described
(Gillet et al, 2007c).
Plasmids
A fusion of the N-terminal half of gB to human IgG1-Fc has been
described (Gillet et al, 2007a). Deletion mutants of this construct
corresponding to the gB 2–6, 2–14 and 2–30 virus mutants were
made by PCR ampliﬁcation of the same region using DNA from
each mutant virus as a template. As with the wild type (Gillet et al,
2007a), each PCR product was cloned into the XbaI/NotI sites of
pTORSTEN, using AvrII and NotI restriction sites in the respective 50
and 30 primers. Fusion proteins were generated by transfecting each
plasmid into 293T cells and harvesting the supernatant 48h later.
Southern blotting
DNAwas extracted from virions (Wizard genomic DNA puriﬁcation
kit; Promega Corporation), digested with EcoRI, electrophoresed
through 0.8% agarose in Tris acetate buffer and transferred to
Figure 7 O-linked glycans on the gB N terminus allow virus neutralization by jacalin. (A) BHK-21 or NMuMG cell-derived virions were left
untreated or incubated with biotinylated jacalin (10mg/ml), biotinylated jacalinþphycoerythrin-conjugated streptavidin (10mg/ml) or the gH/
gL-speciﬁc mAb T2C12. Each sample was then compared by plaque assay. Equivalent data were obtained in a repeat experiment. The reduction
in titer by jacalin was signiﬁcantly greater for NMuMG-derived virions than for BHK-21-derived virions (Po0.02 by Student’s t-test). (B) BHK-
21 or NMuMG-derived virions were left untreated (nil) or deglycosylated with sialidase AþO-glycanase (O
 ), then neutralized with gB-NT-
speciﬁc mAbs (MG-15G9, MG-2C10), biotinylated jacalin/phycoerythrin-conjugated streptavidin (jacalin) or a gH/gL-speciﬁc mAb (7E5).
Equivalent data were obtained in a repeat experiment. In contrast to intact virions, there was no signiﬁcant difference in gB-NT-directed mAb
neutralization between deglycosylated NMuMG- and BHK-21-derived virions. Jacalin showed signiﬁcantly better neutralization of intact virions
from NMuMG cells (Po0.03 by Student’s t-test) but not of deglycosylated virions. (C) Wild-type (WT) and gBD2–30 MuHV-4 were grown in
BHK-21 cells or NMuMG cells and then tested for susceptibility to neutralization by jacalin. Equivalent data were obtained in a repeat
experiment. Unlike wild-type virions, the cell type of origin had no signiﬁcant effect on jacalin-mediated neutralization for gBD2–30 virions.
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et al, 2004). A
32P-dCTP-labeled probe (APBiotech, Little Chalfont,
UK) corresponding to genomic coordinates 15001–18025 was
generated by random primer extension (Nonaprimer kit; Qbiogene,
Bingham, UK). Membranes were hybridized with probe (651C,
18h), washed to a stringency of 0.2% SSC, 0.1% SDS and exposed
to X-ray ﬁlm.
Viral genome quantitation
Viral genome loads were measured by real-time PCR (Bennett et al,
2005). Genomic coordinates 24832–25071 were ampliﬁed by PCR
(Rotor Gene 3000; Corbett Research, Cambridge, UK) from 10ng of
DNA extracted (Wizard genomic DNA puriﬁcation kit; Promega
Corporation) from spleens. The PCR products were quantitated with
Sybr green (Invitrogen) and the copy number was calculated by
comparison with a standard curve of cloned MK3 template, serially
diluted in control spleen DNA and ampliﬁed in parallel. Ampliﬁed
products were distinguished from paired primers by melting curve
analysis, and the correct size of the ampliﬁed products was
conﬁrmed by electrophoresis and staining with ethidium bromide.
Virus titrations
For plaque assays, 10-fold virus dilutions were plated onto BHK-21
cell, NMuMG cell or murine embryonic ﬁbroblast monolayers for
2h, then overlaid with 0.3%. carboxymethylcellulose. The mono-
layers were ﬁxed in 10% formaldehyde after 4 days for BHK-21 cells,
after 5 days for murine embryonic ﬁbroblasts and after 6 days for
NMuMG cells. The ﬁxed cells were stained with 0.1% toluidine blue
and plaques were counted with a plate microscope. To titer
infectious virus in lungs, the lungs were homogenized in complete
medium, frozen, thawed and sonicated. Tissue debris was pelleted
by brief centrifugation (1000g, 1min). Infectious virus in homo-
genate supernatants was then measured by plaque assay. Latent
virus in spleens was measured by infectious center assay (de Lima
et al, 2004). Single spleen cell or mediastinal lymph node cell
suspensions were cultured on murine embryonic ﬁbroblast mono-
layers, which were ﬁxed and stained for plaque counting after 6
days. Pre-formed infectious virus—that forming plaques even after
freeze–thawing—contributed o1% of the infectivity recoverable
from lymphoid tissue, so the infectious center assay essentially
measured reactivating latent virus.
Neutralization assays
Viruses were pre-incubated (2h, 371C) with dilutions of mono-
clonal antibody (mAb), immune serum or biotinylated jacalin
(Vector Laboratories, Burlingame, CA) plus streptavidin-phycoery-
thrin (BD Biosciences, Oxford, UK). The virus–antibody or virus–
lectin mixtures were then added to cell monolayers for plaque
assay.
Monoclonal antibodies
All mAbs were derived from MuHV-4-infected BALB/c mice by
fusion with NS0 cells (Ko ¨hler and Milstein, 1975). The mAbs used
in this study are listed in Supplementary Table 1.
Immunoblotting and immunoprecipitation
Virions were lysed in Laemmli’s buffer, denatured (951C, 5min),
resolved by SDS–PAGE and transferred to PVDF membranes
(Boname et al, 2004). The membranes were blocked with 10%
non-fat milk in PBS/0.1% Tween-20, then incubated with MuHV-4-
speciﬁc mAbs. Bound antibody was detected with horseradish
peroxidase-conjugated rabbit anti-mouse IgG pAb (Dako Corpora-
tion, Ely, UK), followed by washing in PBS/0.1% Tween-20,
development with ECL substrate (APBiotech) and exposure to X-
ray ﬁlm. To look for protein associations, virions were lysed
(30min, 41C) in 1% digitonin/50mM Tris–Cl pH 7.4/150mM NaCl/
5mM MgCl2/5mM CaCl2/1mM PMSF plus complete protease
inhibitors (Roche Diagnostics). Insoluble debris was removed by
centrifugation (13000g, 15min). gH was then immunoprecipitated
with mAb 8C1 (IgG2b) plus protein A-sepharose (Sigma Chemical
Co., Poole, UK). The beads were washed 5  in lysis buffer. The
proteins were then eluted and immunoblotted as above, using
IgG2a primary mAbs and a horseradish peroxidase-conjugated goat
anti-mouse IgG2a secondary antibody (Southern Biotech, Birming-
ham, AL).
Deglycosylation
For SDS–PAGE analyzing, virions were lysed, reduced with 2-
mercaptoethanol, denatured in 1% SDS and deglycosylated with
protein N-glycanase or with sialidase AþO-glycanase according to
the manufacturer’s instructions (Prozyme, San Leandro, CA). For
neutralization assays, N- or O-linked glycans were removed with
the same enzymes, but without reduction or denaturation. Thus,
intact virions were incubated with either protein N-glycanase or
sialidase AþO-glycanase (3h, 371C) in PBS/5% fetal calf serum
buffered to pH 6.
Immunoﬂuorescence
Adherent MuHV-4-infected cells were washed in PBS, ﬁxed in 4%
paraformaldehyde, then permeabilized with 1% Triton X-100. Viral
glycoproteins were detected with murine mAbs plus Alexa 488-
conjugated goat anti-mouse IgG (Invitrogen). Nuclei were counter-
stained with DAPI. Fluorescence was visualized with an Olympus
IX70 microscope plus a Retiga 2000R camera line (QImaging) or
with a Leica confocal microscope.
Flow cytometry
Cells exposed to eGFP
þ viruses were washed in PBS and analyzed
directly for green channel ﬂuorescence. For surface staining, cells
were incubated (1h, 41C) with MuHV-4 glycoprotein-speciﬁc mAbs
followed by ﬂuorescein-conjugated rabbit anti-mouse IgG pAb
(Dako Cytomation) or Alexa 633-conjugated goat anti-mouse pAb
(Invitrogen). Fc fusion protein binding was detected with phyco-
erythrin-conjugated goat anti-human pAb (Sigma). All cells were
washed 2  in PBS after each antibody and analyzed on a FACS
Calibur (BD Biosciences).
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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